BiotechTube

Memantine (once daily) + Memantine (twice daily)

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alzheimer Dementia (AD)

Conditions

Alzheimer Dementia (AD)

Trial Timeline

Oct 1, 2015 → Jul 1, 2016

NCT ID
NCT02553928

About Memantine (once daily) + Memantine (twice daily)

Memantine (once daily) + Memantine (twice daily) is a approved stage product being developed by Lundbeck for Alzheimer Dementia (AD). The current trial status is completed. This product is registered under clinical trial identifier NCT02553928. Target conditions include Alzheimer Dementia (AD).

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02553928ApprovedCompleted

Competing Products

20 competing products in Alzheimer Dementia (AD)

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017LeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82